This list is also available from Thomson Reuters (excluding theses, books and patents):
http://www.researcherid.com/rid/I-5340-2012)
Impact factors are from Thomson Reuters with the exception of journals not listed by the Web of Science (marked by an asterisk*),
for which they are calculated based on Scopus data. Updated on April 7th, 2016.
I. Original Articles
|
Impact factor |
Citations |
Dashkevich A, Raissadati A, Syrjälä SO, Zarkada G, Keränen MAI, Tuuminen R, Krebs R, Anisimov A, Jeltsch M, Leppänen V-M, Alitalo K, Nykänen AI, Lemström, KB. Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts: Lymphatic Endothelial VEGFR3 Controls Rejection. Am J Transplant. 2015; in press. |
5.683 |
0 |
Roukens MG, Peterson-Maduro J, Padberg Y, Jeltsch M, Leppänen V-M, Bos FL, Alitalo K, Schulte-Merker S, Schulte D. Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. Circ Res. 2015; 116 (10): 1660-1669. |
11.019 |
1 |
Batchu KC, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysis. J Biol Chem. 2015; 290 (16): 10093-10103. |
4.573 |
0 |
Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppänen V-M, Holopainen T, Kivelä R, Ortega S, Kärpanen T, Alitalo K. CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3–Mediated Vascular Endothelial Growth Factor-C Activation. Circulation. 2014; 129 (19): 1962–71. |
15.073 |
23 |
Anisimov A, Leppanen V-M, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, Kaijalainen S, Alitalo K. The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands. Sci Signal. 2013; 6 (282): ra52. |
6.279 |
8 |
Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, Orsenigo F, Gaál EI, Holopainen T, Koh YJ, Tammela T, Korpisalo P, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Dejana E, Koh GY, Choi C, Saharinen P, et al. Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic Angiogenesis. Circulation. 2013; 127 (4): 424–34. |
15.073 |
15 |
Leppänen V-M, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, Markovic-Mueller S, Stuttfeld E, Goldie KN, Ballmer-Hofer K, Alitalo K. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. PNAS. 2013; 110 (32): 12960–5. |
9.674 |
12 |
Villefranc JA, Nicoli S, Bentley K, Jeltsch M, Zarkada G, Moore JC, Gerhardt H, Alitalo K, Lawson ND. A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development. 2013; 140 (7): 1497–506. |
6.462 |
22 |
Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, Nykanen AI, Lemstrom KB. Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis. Am J Pathol. 2012; 181 (5): 1607–20. |
4.591 |
11 |
Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, Koskinen PK, Nykanen AI, Lemstrom KB. VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. J Heart Lung Transpl. 2011; 30 (4): S118–S118. |
6.650 |
1 |
Leppanen V-M*, Jeltsch M*, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Ylä-Herttuala S, Ballmer-Hofer K, Alitalo K. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood. 2011; 117 (5): 1507–15. *shared first authorship |
10.452 |
37 |
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, Lorentz P, Jeltsch M, Alitalo K, Eriksson U, Christofori G, Pietras K. Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. PLoS ONE. 2010; 5(11). |
3.234 |
22 |
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, Carmeliet P, Lemström KB, Shibuya M, Ylä-Herttuala S, Alhonen L, Mervaala E, Andersson LC, Knuuti J, Alitalo K. Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. Circulation. 2010; 122 (17): 1725–33. |
15.073 |
48 |
Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. PNAS. 2010; 107 (6): 2425–30. |
9.674 |
78 |
Saharinen P, Helotera H, Miettinen J, Norrmen C, D’Amico G, Jeltsch M, Langenberg T, Vandevelde W, Ny A, Dewerchin M, Carmeliet P, Alitalo K. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Gene Dev. 2010; 24 (9): 875–80. |
10.798 |
12 |
Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell. 2010; 18 (6): 630–40. |
23.523 |
64 |
Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, Jeltsch M, Ylä-Herttuala S, Alitalo K. Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle. Circ Res. 2009; 104 (11): 1302–12. |
11.019 |
38 |
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, Wedge SR, Jurgensmeier JM, Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008; 68 (12): 4754–62. |
9.329 |
65 |
Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E, Leskinen H, Kivela R, Helkamaa T, Merentie M, Jeltsch M, Paavonen K, Andersson LC, Mervaala E, Hassinen IE, Yla-Herttuala S, Oresic M, Alitalo K. Overexpression of Vascular Endothelial Growth Factor-B in Mouse Heart Alters Cardiac Lipid Metabolism and Induces Myocardial Hypertrophy. Circ Res. 2008; 103 (9): 1018–U247. |
11.019 |
55 |
Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, Jeltsch M, Juan TD, Sievers RE, Chorianopoulos E, Wada H, Vanwildemeersch M, Noel A, Foidart J-M, Springer ML, von Degenfeld G, Dewerchin M, Blau HM, Alitalo K, et al. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. 2008; 28 (9): 1614–20. |
6.008 |
53 |
Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, Yla-Herttuala S, Alitalo K. Enhanced Capillary Formation Stimulated by a Chimeric Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor-C Silk Domain Fusion Protein. Circ Res. 2007; 100 (10): 1460–7. |
11.019 |
10 |
Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, Alitalo K. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res. 2007; 100 (10): 1468–75. |
11.019 |
19 |
Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular Endothelial Growth Factor (VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns. J Biol Chem. 2006; 281 (17): 12187–95. |
4.573 |
18 |
Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, Alitalo K. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006; 20 (9): 1462–72. |
5.043 |
158 |
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Ylä-Herttuala S, Jackson DG, Alitalo K, McDonald DM. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005; 115 (2): 247–57. |
13.262 |
305 |
He YL, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005; 65 (11): 4739–46. |
9.329 |
220 |
Krebs R, Tikkanen JM, Nykanen AI, Wood J, Jeltsch M, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Resp Crit Care. 2005; 171 (12): 1421–9. |
12.996 |
25 |
Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003; 161 (6): 1163–77. |
9.834 |
1086 |
Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2003; 5 (1): 74–80. |
20.004 |
614 |
Veikkola T, Lohela M, Ikenberg K, Makinen T, Korff T, Saaristo A, Petrova T, Jeltsch M, Augustin HG, Alitalo K. Intrinsic versus micro environmental regulation of lymphatic endothelial cell phenotype and function. FASEB J. 2003; 17 (14): 2006–13. |
5.043 |
56 |
Saaristo A, Veikkola T, Enholm B, Hytonen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Yla-Herttuala S, Alitalo K. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J. 2002; 16 (9): 1041–9. |
5.043 |
90 |
Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res. 2001; 88 (6): 623–9. |
11.089 |
133 |
Veikkola T, Jussila L, Mäkinen T, Kärpänen T, Jeltsch M, Petrova T, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001; 20 (6): 1223- 31. |
10.434 |
398 |
Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001; 20 (4): 672–82. |
10.434 |
631 |
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, Laukkanen J, Niemi M, Kossila M, Hakkinen TP, Kivela A, Enholm B, Mansukoski H, Turunen AM, Alitalo K, Yla-Herttuala S. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 2000; 102 (18): 2262–8. |
15.073 |
92 |
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). PNAS. 1998; 95 (2): 548–53. |
9.674 |
758 |
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch M, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. PNAS. 1998; 95 (20): 11709–14. |
9.674 |
332 |
Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 1998; 177 (3): 439–52. |
3.839 |
125 |
Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem. 1997; 272 (40): 25176–83. |
4.573 |
126 |
Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice. Science. 1997; 276 (5317): 1423–5. |
33.611 |
842 |
Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997; 16 (13): 3898–911. |
10.434 |
480 |
Oh S-J, Jeltsch M, Birkenhäger R, McCarthy JEG, Weich HA, Christ B, Alitalo K, Wilting J. VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane. Dev Biol. 1997; 188 (1): 96–109. |
3.547 |
344 |
Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular. Development. 1996; 122 (12): 3829–37. |
6.462 |
418 |
II. Review Articles
Mattonet K, Jeltsch M. Heterogeneity of the origin of the lymphatic vascular system. [German] [English] Lymphforsch. 2015; 19 (2): 2-5. |
1,469* |
0 |
Krebs R, Lackner M, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 2: The role of VEGF-C and VEGF-D in lymphatic system diseases. [German] Vasomed. 2014; 26 (1): 48–50. |
0,230* |
0 |
Jeltsch M, Leppanen V-M, Saharinen P, Alitalo K. Receptor Tyrosine Kinase-Mediated Angiogenesis. CSH Perspect Biol. 2013; 5 (9): a009183–a009183. |
8.679 |
24 |
Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 1. Grundlagen und Embryonalentwicklung. [German] Lymphforsch. 2013; 17 (1): 30–7. |
1,469* |
0 |
Krebs R, Jeltsch M. Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 2. Die Rolle von VEGF-C und VEGF-D bei Krankheiten des Lymphgefäßsystems. [German] Lymphforsch. 2013; 17 (2): 96–104. |
1,469* |
0 |
Krebs R, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Fundamentals and embryonic development. [German] Vasomed. 2013; 25 (6): 335–6. |
0,230* |
0 |
Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res. 2003; 314 (1): 69–84. |
3.565 |
52 |
Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotech. 1999; 10 (6): 528–35. |
7.117 |
115 |
Joukov V, Kaipainen A, Jeltsch M, Pajusola K, Olofsson B, Kumar V, Eriksson U, Alitalo K. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol. 1997; 173 (2): 211–5. |
3.839 |
81 |
III. Meeting Abstracts
Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, Stacker S, Alitalo K. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. Clin Canc Res. 2001; 7 (11): 3762S – 3762S. |
8.722 |
0 |
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, Laukkanen J, Niemi M, Kossila M, Häkkinen TP, Kivel ä A, Enholm B, Mansukoski H, Turunen A-M, Alitalo K, Ylä-Herttuala S. VEGF-C adenovirus gene transfer reduces intima formation in rabbits. Atherosclerosis Supplements. 2000; 151 (1): 81. |
2.293 |
0 |
IV. Book Chapters
Saharinen P, Jeltsch M, Santoyo MM, Leppänen V-M, Alitalo K. TIE Receptor Tyrosine Kinase Family. Receptor Tyrosine Kinases: Family and Subfamilies. Springer International Publishing Switzerland; in press. |
Mattonet K, Wilting J, Jeltsch M. Die genetischen Ursachen des primären Lymphödems. In: Weissleder H, Schuchhardt C, editors. Erkrankungen des Lymphgefäßsystems. Cologne: Viavital Verlag; 2015. p. 210-29. |
Jeltsch M, Alitalo K. VEGF Receptors. In: Watling, K., editor. Sigma-RBI Handbook of Receptor Classification and Signal Transduction. Sigma-Aldrich Co. LLC; 2006. p. 338–9. |
IV. Theses
Jeltsch, Michael. VEGFR-3 Ligands and Lymphangiogenesis [Doctoral Thesis]. [Helsinki, Finland]: University of Helsinki; 2002. |
Jeltsch, Michael. Functional Analysis of VEGF-B and VEGF-C [Master’s Thesis]. [Helsinki, Finland]: University of Helsinki; 1997. |
V. Patents, Patent Applications and Invention Disclosures
Date |
Title |
Inventors |
# |
Invention Disclosures |
|
|
|
01.02.1016 |
Rapid generation of monoclonal antibodies |
M. Jeltsch, K. Mattonet, J. Vulli |
0534/2015 (to the University of Helsinki) |
Patent applications |
|
|
|
24.01.2014 |
Methods and uses related to ADAMTS3 |
K. Alitalo, M. Jeltsch, S.K. Jha, D. Tvorogov |
PCT/FI2015/050041 |
12.08.2013 |
Therapeutic use of VEGF-C and CCBE1 |
K. Alitalo, M Jeltsch, A. Anisimov |
PCT/FI2014/050620 |
22.03.2012 |
Modified VEGF-A with improved angiogenic properties |
K. Alitalo, T. Tammela, S. Keskitalo, K. Pajusola, M. Jeltsch, et al. |
|
17.11.2005 |
Use of VEGF-C or VEGF-D gene or protein to prevent restenosis |
K. Alitalo, S. Ylä-Herttuala, M.O. Hiltunen, M. Jeltsch, et al. |
|
06.06.2002 |
Glycosylated VEGF-B, method for increasing the amount of soluble VEGF-B |
M. Jeltsch, K. Alitalo, B. Olofsson, U. Eriksson |
|
Patents |
|
|
|
04.06.2013 |
Use of VEGF-D gene to prevent restenosis |
K. Alitalo, S. Ylä-Herttuala, M.O. Hiltunen, M. Jeltsch, et al. |
|
25.08.2011 |
Materials and methods involving hybrid VEGF DNAs and proteins |
K. Alitalo, M. Jeltsch |
|
24.11.2010 |
VEGFR-2-specific forms of VEGF-D and VEGF-C and uses thereof |
K. Alitalo, M. Jeltsch, V.-M. Leppänen, K. Aho, A. Anisimov, D. Tvorogov |
|
18.06.2009 |
Growth factor binding constructs materials and methods |
K. Alitalo, M. Jeltsch |
|
09.02.2006 |
VEGFR-3 fusion proteins |
K. Alitalo, M. Jeltsch |
|
25.10.2005 |
Use of VEGF-C to prevent restenosis |
K. Alitalo, S. Ylä-Herttuala, M.O. Hiltunen, M. Jeltsch, et al. |